SCHEMBL7355194

SCHEMBL7355194

CCCCCCC(CC)n1nnc2c(=O)[nH]c(C(Cc3ccccc3)C3=COCO3)nc21

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.34
HPGD P15428 2/20 0.32
HTT P42858 2/20 0.32
ALDH1A1 P00352 1/20 0.32
TP53 P04637 1/20 0.32
GAA P10253 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
CASP1 P29466 1/20 0.32
CASP7 P55210 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HDAC8 Q9BY41 1/20 0.31
KDM1A O60341 1/20 0.31
RAD51 Q06609 1/20 0.31
HSD17B10 Q99714 1/20 0.30
PDE5A O76074 1/20 0.30
PDE1A P54750 1/20 0.30
PDE1B Q01064 1/20 0.30
PDE1C Q14123 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7356646 0.81 KMT2A (0.33) KMT2AHPGDTSHRRAD51
SCHEMBL1864507 0.62
SCHEMBL28206541 0.59 PARP1 (0.51) KMT2AALDH1A1HSD17B10
SCHEMBL28206020 0.57 PARP1 (0.52) KMT2AALDH1A1HSD17B10
SCHEMBL3749372 0.57 ALDH1A1 (0.33) HPGDALDH1A1GAA
SCHEMBL4380565 0.57 CHRM1 (0.51) ALDH1A1TP53HSD17B10
SCHEMBL14732066 0.57 NPY5R (0.41)
SCHEMBL2870974 0.56 TLR8 (0.36)
SCHEMBL4234776 0.56 CYP1A2 (0.33)
SCHEMBL5180934 0.56 SLC6A2 (0.50) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107847462-B Targeting cGMP-related phosphodiesterases to reduce cyst formation of cystic kidney disease and related materials and methods 美国印第安纳大学研究和技术公司 2021-08-10 CN disclosed
EP-1107968-B1 DIHYDRO-[1,2,3]TRIAZOLO-[4,5-D]PYRIMIDIN-7-ONE BAYER AG (DE) 2002-11-13 EP disclosed
US-6458796-B1 METHOD OF TREATING CARDIOVASCULAR DISORDERS, THROMBOEMBOLIC DISORDERS AND ISCHAEMIAS, AND UROGENITAL SYSTEM DISORDERS, COMPRISING ADMINISTERING TO MAMMALS BAYER AKTIENGESELLSCHAFT (DE) 2002-10-01 US disclosed